Bevacizumab (Avastin)
From Glioblastoma Treatments
| Property | Information |
|---|---|
| Drug Name | Bevacizumab (Avastin) |
| FDA Approval | Yes, for recurrent glioblastoma |
| Used for | Glioblastoma |
| Clinical Trial Phase | Phase III |
| Clinical Trial Explanation | Not specified |
| Common Side Effects | Hypertension, proteinuria, and hemorrhage |
| OS without | Not specified |
| OS with | AVAglio trial: 16.8 months; RTOG trial: 15.7 months |
| PFS without | Not specified |
| PFS with | Not specified |
| Usefulness Rating | 4 |
| Usefulness Explanation | Not specified |
| Toxicity Level | 3 |
| Toxicity Explanation | Bevacizumab has an intermediate level of toxicity. Although it is a powerful medication against glioblastoma, it can have serious side effects including high blood pressure (hypertension), presence of excess proteins in the urine (proteinuria), and bleeding (hemorrhage). These side effects can impact your general health and daily activities. Therefore, this treatment needs regular monitoring by your health care provider and should be used with caution. |
Notes: Avastin improves PFS when used initially, but no significant benefit for overall survival compared to Avastin given at recurrence.
From Ben Williams Book: Not specified
Loading comments...
